Get the Stockscreener App
1.88
1.08%
0.02
Nervgen Pharma Corp stock is traded at $1.88, with a volume of 785.60K.
It is up +1.08% in the last 24 hours and up +8.67% over the past month.
NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.
See More
Previous Close:
$1.86
Open:
$1.92
24h Volume:
785.60K
Relative Volume:
0.99
Market Cap:
$200.06M
Revenue:
-
Net Income/Loss:
$-31.64M
P/E Ratio:
-4.4487
EPS:
-0.4226
Net Cash Flow:
$-13.98M
1W Performance:
-11.32%
1M Performance:
+8.67%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$1.80
$1.94
1-Week Range:
$1.80
$2.16
52-Week Range:
$1.70
$5.9299
Nervgen Pharma Corp Stock (NGEN) Company Profile
Compare NGEN vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NGEN
Nervgen Pharma Corp
|
1.88 | 200.06M | 0 | -31.64M | -13.98M | -0.4226 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Nervgen Pharma Corp Stock (NGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-27-26 | Initiated | H.C. Wainwright | Buy |
Nervgen Pharma Corp Stock (NGEN) Latest News
Lobbying Update: $50,000 of NERVGEN PHARMA CORP. lobbying was just disclosed - Quiver Quantitative
If You Invested $1,000 in Nervgen Pharma Corp (NGENF) - Stock Titan
NGEN Q3 2025 Earnings: Narrow EPS Beat Masks Continued Pre-Revenue Stage, Stock Sheds Nearly 7%EPS Consistency Score - dars.gov.et
Breakthrough peptide repairs nerves after spinal cord injury in clinical trial - BioXconomy
NervGen Pharma (NGEN) Q3 2025 Earnings: Small EPS Beat Amid Ongoing Clinical Development and Cash ManagementEarnings Growth Analysis - dars.gov.et
NervGen Pharma(NGEN) Stock Options Chain | Quotes & News - Moomoo
NervGen Pharma remains a Buy after FDA aligns o... - Pluang
NervGen Pharma: I Think The Biggest Risks Are Now Behind It (NASDAQ:NGEN) - Seeking Alpha
Enterprise value to revenue forward of NervGen Pharma Corp. – NASDAQ:NGEN - TradingView
Price to book forward of NervGen Pharma Corp. – NASDAQ:NGEN - TradingView
Price to sales forward of NervGen Pharma Corp. – NASDAQ:NGEN - TradingView
NervGen Pharma Corp. Actuals & Estimates (NASDAQ:NGEN) - TradingView
NGEN Forecast — Price Target — Prediction for 2027 - TradingView
9UA Forecast — Price Target — Prediction for 2027 - TradingView
NervGen Pharma Corp. Actuals & Estimates (FWB:9UA) - TradingView
NervGen Pharma Corp. Actuals & Estimates (DUS:9UA) - TradingView
NervGen rises as TD Cowen issues new BUY on lead asset - MSN
NervGen Pharma Corp. (NGEN) Q3 2025 Earnings: Slight EPS Beat Highlights Disciplined Expense Management in Pre-Revenue StageFull Year Guidance - dars.gov.et
Spinal Cord Injury Pipeline 2026: Therapies, MOA Insights, and Key Clinical Trial Updates By DelveInsight | StemCyte, NervGen Pharma, VA Office of Research and Development, Kessler Institute for Rehab - Barchart.com
Nervgen Pharma Ord Shs (NGEN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Nervgen Pharma Ord Shs (NGEN) Institutional Confidence - TradingKey
Nervgen Pharma Ord Shs (NGEN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Nervgen Pharma Ord Shs (NGEN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Nervgen Pharma Ord Shs (NGEN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Nervgen Pharma Ord Shs (NGEN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Nervgen Pharma Ord Shs (NGEN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Spinal Cord Injury Market Trends, Innovation, and Future Growth Outlook to 2036 – DelveInsight | Nipro Corp, Kringle Pharma, Abbvie, Neuroplast, Mitsubishi Tanabe Pharma America, Kringle Pharma - Barchart.com
Nervgen Pharma Ord Shs (NGEN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
NervGen Pharma Corp. Financial Disclosures & SEC Filings - TradingView
NervGen Pharma (NGEN) Investor Relations, Earnings Summary & Outlook - Quartr
NervGen Pharma (NGEN) Receives Buy Rating from TD Cowen, Shares Rally - GuruFocus
NervGen stock rises as TD Cowen issues new Buy (NGEN:NASDAQ) - Seeking Alpha
NervGen stock initiated at Buy by TD Cowen ahead of phase 3 trial - Investing.com UK
ORIC Pharmaceuticals Positions for Growth in Expanding Oncology Market - Streetwise Reports
NervGen Pharma (NGEN) Slips 7.5% as Selling Pressure Mounts: Key Support Levels in FocusWMA Signal - dars.gov.et
NGEN Q3 2025 Earnings: Narrowed Loss Beat Estimates as Pipeline AdvancesSubscription Growth Report - dars.gov.et
California Pharma Co. Tests Breakthrough Cancer Drug, Cuts Death Risk 60% - Streetwise Reports
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
NervGen Pharma Raises US$60 Million in Underwritten Offering to Fund NVG-291 Program - TipRanks
United StatesMintz Advises On NervGen Pharma’s $60 Million Public Offering - Mondaq
US Biotech Co. Targets Muscular Dystrophy with First-In-Class Drug - Streetwise Reports
Nervgen’s CONNECT Trial Termination: What It Means for NGEN Investors - TipRanks
Biopharma Company Reveals High-Impact SCI Recovery Gains - Streetwise Reports
NGEN Stock Price and Chart — NASDAQ:NGEN - TradingView
NervGen Pharma Company Profile & Introduction - Moomoo
How one School of Medicine researcher’s legacy offers hope for those with spinal cord injuries - Case Western Reserve University
These stocks have an unusual volume in today's session - ChartMill
NervGen reports positive gait analysis data for NVG-291 trial - grafa.com
NervGen Pharma (NGEN) Reports Promising Gait Analysis Results - GuruFocus
Why Is NervGen Pharma Stock Gaining Tuesday? - Benzinga
NervGen reports positive gait analysis data for NVG-291 trial By Investing.com - Investing.com Australia
Nervgen Pharma Corp Stock (NGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):